Argenx says Vyvgart sales rose 54% in third quarter
Argenx reported a 54% increase in Vyvgart sales to $1.7B in Q3, treating generalized myasthenia gravis. Operating profit was $486M, below estimates. The company completed a $2.2B acquisition of Forte Biosciences, adding a drug for vitiligo and celiac disease. Operating margin declined to 28.2% due to acquisition costs, and R&D expenses are expected to reach $4B by 2026.
How this was made
The 30-second read
Why it matters
The earnings miss may trigger a sell‑off, but the strong sales growth and new pipeline assets could support a rebound.
Market read
First‑time Q3 earnings release with material numbers; relevant for biotech and specialty‑pharma traders.
What to watch
Potential upside from the recent Forte Biosciences acquisition and pipeline expansion.
Background
Argenx, a Belgian‑Dutch biotech, disclosed its Q3 results and completed a $2.2 bn acquisition of Forte Biosciences.
Ticker impact
Argenx reported Q3 sales of $1.7 bn, up 54%, but operating profit missed estimates at $486 m.
likely downward pressure as investors price in lower-than-expected profit
Revenue beat is offset by a profit shortfall and higher acquisition costs, which typically depress near‑term price.
Market effects
Biotech/autoimmune drug sector may see mixed sentiment as sales growth is strong but margins compress.
European biotech markets could react modestly given argenx's dual‑listing.
Limited to investors focused on specialty pharma earnings.
Counterpoint
The sales surge could signal a longer‑term growth runway, outweighing short‑term profit miss.
Key entities
- companyargenx
Biopharma firm reporting Q3 results
- companyForte Biosciences
Acquired biotech adding vitiligo and celiac pipeline
